Ondansetron Use During Pregnancy: Birth Defects and Obstetric Outcomes.
antiemetics
birth defects
congenital heart defects
hyperemesis gravidarum
ondansetron
Journal
Clinical nursing research
ISSN: 1552-3799
Titre abrégé: Clin Nurs Res
Pays: United States
ID NLM: 9208508
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
medline:
24
4
2023
pubmed:
14
3
2023
entrez:
13
3
2023
Statut:
ppublish
Résumé
Ondansetron is a widely administered medication for nausea and vomiting of pregnancy. Further examination of its teratogenic capacity is necessary. This study examines the association between ondansetron treatment during pregnancy and birth defects and adverse obstetric outcomes. Patient data were extracted from Clalit Health Services, Israel. A propensity-score analysis was performed matching those exposed to ondansetron with those who were not. Findings identified 774 women exposed to ondansetron, matched 1:1 with unexposed control patients. No significant differences were found between the groups for: cleft palate, cardiovascular congenital abnormalities, spina bifida occulta, preterm delivery, or small for gestational age. Ondansetron may be a useful and safe alternative as treatment for women who suffer from hyperemesis gravidarum and do not respond to other antiemetic drugs. Notwithstanding, additional prospectively designed research is needed to establish the safety of ondansetron treatment during pregnancy.
Identifiants
pubmed: 36912091
doi: 10.1177/10547738231159062
doi:
Substances chimiques
Ondansetron
4AF302ESOS
Antiemetics
0
Types de publication
Journal Article
Langues
eng